The science and methodologies required to perform the Endocrine Disruptor Screening Program’s Tier 1 In Vivo Mammalian Assays will be discussed including the nature of the reproductive and general toxicity endpoints and the alterations that may signal endocrine disruption.
As the Male and Female Pubertal studies can be performed as a Combined Male and Female Pubertal Study, the advantages and disadvantages of the combined assay will also be discussed.
Regulatory agencies have consistently agreed that endocrine disruption must be evaluated by “Weight of Evidence” (WoE) procedures. A discussion of the relative weight for each endpoint and the use of the hypothesis-based “WoE” approach for determination a positive response in this assay will be discussed.
More info at http://www.huntingdon.com/Chemical/Endocrinedisruptorscreeningprogram/Webinars